Fairbanks Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.56M Sell
3,115
-52
-2% -$25K 0.92% 28
2026
Q1
$1.56M Sell
3,167
-68
-2% -$36.9K 0.97% 31
2025
Q4
$1.87M Sell
3,235
-13
-0.4% -$7.35K 1.03% 29
2025
Q3
$1.58M Buy
3,248
+1,421
+78% +$661K 0.85% 34
2025
Q2
$741K Buy
1,827
+115
+7% +$48.1K 0.42% 41
2025
Q1
$852K Sell
1,712
-3
-0.2% -$1.63K 0.55% 40
2024
Q4
$892K Buy
+1,715
New +$943K 0.56% 39

Other funds holding TMO

Fairbanks Capital Management's TMO Position: Q2 2026 in Review

Fairbanks Capital Management reduced its Thermo Fisher Scientific (TMO) stake by 1.6% in Q2 2026, selling an estimated $25K and leaving 3,115 shares worth $1.56M. The position accounts for 0.92% of the portfolio, ranked #28.

Fairbanks Capital Management first reported a position in TMO in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.87M in Q4 2025. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Fairbanks Capital Management held 3,115 shares of Thermo Fisher Scientific worth $1.56M as of Q2 2026.
  • Fairbanks Capital Management sold 52 Thermo Fisher Scientific shares in Q2 2026, an estimated $25K.
  • Thermo Fisher Scientific made up 0.92% of Fairbanks Capital Management's portfolio in Q2 2026, its #28 holding.
  • Fairbanks Capital Management first reported a position in Thermo Fisher Scientific in Q4 2024 and has held it in 7 quarters since.
  • Fairbanks Capital Management's Thermo Fisher Scientific position peaked at $1.87M in Q4 2025.
  • 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Fairbanks Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.